SillaJen, Inc.
215600.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$323.22B
Close$
Share Statistics
| Market cap | $323.22 Billion |
|---|---|
| Enterprise Value | $318.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-175.95 |
| Beta | -0.02 |
| Outstanding Shares | 138,516,313 |
Return
| Return on Equity | -23.95% |
|---|---|
| Return on Assets | -22.46% |
| Return on Invested Capital | -25.00% |
Valuation & Multiples
| P/E Ratio | -13.41 |
|---|---|
| PEG | 3528.55 |
| Price to Sales | 28.96 |
| Price to Book Ratio | 3.07 |
| Enterprise Value to Revenue | 29.58 |
| Enterprise Value to EBIT | -12.55 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SillaJen, Inc.
43 employees
CEO: Jaekyung Kim SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late...